tigger transposable element derived 3Genealiases: []
Q-omics provides the consensus-scored TIGD3 profile across patient tissues and cancer cell-line models. TIGD3 expression is associated with patient survival in 31 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, TIGD3 is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, TIGD3 RNA expression shows 17,426 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KICH, COAD, and LSCC as cancer lineages where TIGD3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TIGD3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TIGD3 survival associations across molecular data types. TIGD3 RNA expression shows survival associations in the most cancer types (31), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TIGD3 RNA expression–survival associations across cancer types. High TIGD3 expression shows unfavorable associations in KICH and COAD, but favorable associations in HNSC, SKCM, LGG and LUSC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .006). Together, the overview and detailed table identify KICH as the clearest survival context for TIGD3 RNA expression.
This table summarizes TIGD3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for TIGD3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TIGD3 shows higher tumor expression in COAD, LIHC, LUAD, HNSC, UCEC and BRCA. The COAD box plot shows higher TIGD3 RNA expression in tumor versus normal tissue (log2 FC = +0.683, t-test p < 0.001).
This table shows molecular features associated with TIGD3 in patient tissues and cancer cell lines. In patient samples, TIGD3 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, TIGD3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Leukemia.
